<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232076">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055874</url>
  </required_header>
  <id_info>
    <org_study_id>III-MK-CML-IV</org_study_id>
    <secondary_id>CDR0000271424</secondary_id>
    <secondary_id>EU-20248</secondary_id>
    <nct_id>NCT00055874</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>III. Medizinische Klinik Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth
      of cancer cells. It also helps stop the patient's immune system from rejecting the donor's
      stem cells. Also, imatinib mesylate may stop the growth of cancer cells by blocking the
      enzymes needed for cancer cell growth. Interferon alfa may interfere with the growth of
      cancer cells and slow the growth of cancer. When the healthy stem cells from a donor are
      infused into the patient they may help the patient's bone marrow make stem cells, red blood
      cells, white blood cells, and platelets. It is not yet known which treatment regimen is most
      effective in treating chronic phase chronic myelogenous leukemia.

      PURPOSE: This randomized phase III trial is studying imatinib mesylate with or without
      interferon alfa or cytarabine to see how well it works compared with interferon alfa
      followed by donor stem cell transplant in treating patients with newly diagnosed chronic
      phase chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the hematologic, cytogenetic, and molecular response rates in patients with
           newly diagnosed chronic phase chronic myelogenous leukemia treated with imatinib
           mesylate alone or with interferon alfa or low-dose cytarabine vs interferon alfa
           standard therapy.

        -  Compare the group-dependent, progression-free and overall survival and time to
           progression in patients treated with these regimens.

        -  Compare the efficacy of allogeneic stem cell transplantation vs imatinib mesylate-based
           therapy in patients eligible for transplantation.

        -  Compare the efficacy of reduced-intensity conditioning vs standard conditioning in
           patients over 45 years of age.

        -  Determine the time to and duration of hematologic, cytogenetic, and molecular responses
           and correlate these factors in patients treated with these regimens.

        -  Compare the short- and long-term adverse effects of these regimens in these patients.

        -  Compare the presentation, duration, and responses to therapy of accelerated and blastic
           phases in patients treated with these regimens.

        -  Determine the survival of high-risk patients after early allografting.

        -  Determine the influence of pre-transplantation therapies on the outcome of allogeneic
           stem cell transplantation in these patients.

      OUTLINE: This is a randomized, multicenter, pilot study. Patients are stratified according
      to participating center. Patients with low- to intermediate-risk disease are randomized to 1
      of 4 treatment arms. Patients with high-risk disease are randomized to 1 of 3 treatment arms
      with imatinib mesylate-based regimens.

        -  Arm I: Patients receive oral imatinib mesylate once daily for up to 12 months in the
           absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients receive oral imatinib mesylate as in arm I. Patients also receive
           interferon alfa subcutaneously (SC) 3 times a week beginning at least 3 months after
           the start of imatinib mesylate.

        -  Arm III: Patients receive oral imatinib mesylate as in arm I. Patients also receive
           cytarabine SC up to twice daily for 5 days monthly beginning at least 3 months after
           the start of imatinib mesylate.

        -  Arm IV: After initial cytoreduction with hydroxyurea, patients receive interferon alfa
           SC daily with or without hydroxyurea. In the absence of a complete response after 3
           months, patients may also receive low-dose cytarabine SC once daily. Treatment
           continues for up to 21 months.

      Patients who fail interferon alfa therapy are crossed over to receive imatinib mesylate.

      Patients who fail therapy with imatinib mesylate and are eligible for an allogeneic
      transplantation are stratified according to availability of donor (HLA-identical related vs
      unrelated), status, and participating center. Patients are randomized to receive an
      allogeneic transplantation or continue any salvage therapy.

      Patients who are not eligible for allogeneic transplantation receive hydroxyurea and
      cytarabine or high-dose chemotherapy with autologous stem cell rescue followed by
      interferon- or imatinib mesylate-based therapy.

      Patients over 45 years of age are further randomized to receive an age-adjusted standard
      conditioning regimen or reduced intensity preparative regimen (mini transplantation) prior
      to allogeneic transplantation.

      Patients are followed every 6 months for 3 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 1,600 patients (400 per treatment arm) will be accrued for
      this study within 4-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk group-dependent survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic, cytogenetic, and molecular response rates</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed chronic phase chronic myelogenous leukemia (CML)

               -  bcr-abl positive

               -  No blasts, promyelocytes, myelocytes, or metamyelocytes in the peripheral blood

          -  Availability of a HLA-identical sibling or unrelated donor

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No second malignancy requiring therapy

          -  No evidence of disease-related symptoms or extramedullary disease (including
             hepatosplenomegaly)

          -  No serious diseases that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior interferon

        Chemotherapy

          -  No prior chemotherapy other than hydroxyurea

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  Not specified

        Other

          -  Prior anagrelide allowed

          -  No participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruediger Hehlmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>III. Medizinische Klinik Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus / Klinikum Krefeld</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Johnen, MD</last_name>
      <phone>49-241-736-08</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Aurich</name>
      <address>
        <city>Aurich</city>
        <zip>26603</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Langer, MD</last_name>
      <phone>49-4941-94-5000</phone>
      <email>langer@kkh-aurich.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus</name>
      <address>
        <city>Bad Hersfeld</city>
        <zip>36251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P J Majunke, MD</last_name>
      <phone>49-6621-881779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Hedwig Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Boewer, MD</last_name>
      <phone>49-30-2311-2255</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haematologisch-Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>13357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Blau, MD</last_name>
      <phone>49-30-461-4857</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Haematologie und Internistische Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Sperling, MD</last_name>
      <phone>49-30-2804-1960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Haematologie und Internistische Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>D-12103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Ludwig, MD</last_name>
      <phone>49-30-757-047-20</phone>
      <email>onkopraxis-lmu@GMX.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33602</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Just, MD</last_name>
      <phone>49-521-137-930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augustinum</name>
      <address>
        <city>Bonn</city>
        <zip>D-53117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Grips, MD</last_name>
      <phone>49-228-67-38-00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamatologische Sprechstunde</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fischer-Lampsatis, MD</last_name>
      <phone>49-3381-411-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. F.&amp; G. Doering</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Doering, MD</last_name>
      <phone>49-421-498-5068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Kliniken Delmenhorst</name>
      <address>
        <city>Delmenhorst</city>
        <zip>27753</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Funke, MD</last_name>
      <phone>49-4221-994-101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Duehrsen</last_name>
      <phone>49-201-723-2417</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Essen Werden</name>
      <address>
        <city>Essen</city>
        <zip>D-45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Karl Baur, MD</last_name>
      <phone>49-201-4089-2099</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Hoelzer, MD, PhD</last_name>
      <phone>49-69-6301-5194</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internistische Praxisgemeinschaft</name>
      <address>
        <city>Germering</city>
        <zip>82110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Mittermueller, MD</last_name>
      <phone>49-89-842-910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DR Herbert - Nieper Krankenhaus Goslar</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hoyer, MD</last_name>
      <phone>49-5321-555-401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Gottingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Binder, MD, PhD</last_name>
      <phone>49-551-39-2331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Eimermacher, MD</last_name>
      <phone>49-2331-129-250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rutjes, MD</last_name>
      <phone>49-40-2890-2416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, MD, PhD</last_name>
      <phone>49-404-2803-4315</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelische Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <zip>DOH-59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leopold Balleisen, MD</last_name>
      <phone>49-2381-589-1333</phone>
      <email>LBalleisen@evkhamm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik und Poliklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony D. Ho, MD, PhD</last_name>
      <phone>49-6221-56-8001</phone>
      <email>anthony_ho@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke Brants</last_name>
      <phone>49-6221-56-8006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruprecht - Karls - Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Fruehauf, MD</last_name>
      <phone>49-622-156-8085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Hospital Homburg</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans W. Pees, MD</last_name>
      <phone>49-6841-162-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>D-66424</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael G.M. Pfreundschuh, MD</last_name>
      <phone>49-6841-162-3084</phone>
      <email>michael.pfreundschuh@uniklinik-saarland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>D-67653</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Buhl</last_name>
      <phone>49-631-203-1872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-721-974-1390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincentius - Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Goeckel, MD</last_name>
      <phone>49-721-8108-3035</phone>
      <email>gerhard.goeckel@vincentius-ka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten Oberallgaeu</name>
      <address>
        <city>Kempten</city>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gatter, MD</last_name>
      <phone>49-831-530-2226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Schoch, MD</last_name>
      <phone>49-431-1697-5226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Krefeld GmbH</name>
      <address>
        <city>Krefeld</city>
        <zip>D-47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Helmer, MD</last_name>
      <phone>49-2151-32-2709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internistisches Fachaerzte Zentrum Langen</name>
      <address>
        <city>Langen</city>
        <zip>D-63225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Koehler, MD</last_name>
      <phone>49-61-032-8787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas - Krakenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Jost, MD</last_name>
      <phone>49-6881-501-273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis - Leer</name>
      <address>
        <city>Leer</city>
        <zip>D-26789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Mueller, MD</last_name>
      <phone>49-491-987-910</phone>
      <email>Lothar.Mueller@onkologie-leer.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe - Lemgo</name>
      <address>
        <city>Lemgo</city>
        <zip>D-32657</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-52-6126-4123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>D-67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrich, MD</last_name>
      <phone>49-621-503-3900</phone>
      <email>henrichd@klilu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68305</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schatz, MD</last_name>
      <phone>49-621-383-4114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Maria-Hilf II</name>
      <address>
        <city>Monchengladbach</city>
        <zip>D-41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lange, MD</last_name>
      <phone>49-2161-892-2212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Muenchen Schwabing</name>
      <address>
        <city>Muenchen</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Fischer, MD</last_name>
      <phone>49-89-3068-2389</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haematologisch - Onkologische Gemeinschaftspraxis - Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Wehmeyer, MD</last_name>
      <phone>49-251-620-080</phone>
      <email>wehmeyer@onkologie-muenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Haferlach, MD</last_name>
      <phone>49-89-7095-4970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haematologische Schwerpunktpraxis</name>
      <address>
        <city>Munich</city>
        <zip>D-81679</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Hitz, MD</last_name>
      <phone>49-89-9972-0275</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematologische Onkologische Praxis</name>
      <address>
        <city>Regensburg</city>
        <zip>93047</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Dengler, MD</last_name>
      <phone>49-941-566-342</phone>
      <email>robert.dougler@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93042</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan W. Krause, MD</last_name>
      <phone>49-941-944-5538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Remscheid GmbH</name>
      <address>
        <city>Remscheid</city>
        <zip>D-42859</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Wehmeier, MD</last_name>
      <phone>49-21-9113-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktpraxis</name>
      <address>
        <city>Russelsheim</city>
        <zip>65428</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Baldus, MD</last_name>
      <phone>49-6142-940-321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonie - Krankenhaus</name>
      <address>
        <city>Schwaebisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Geer, MD</last_name>
      <phone>49-791-753-4411</phone>
      <email>tgeer@diaksha.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marien - Krankenhaus Siegen GMBH</name>
      <address>
        <city>Siegen</city>
        <zip>D-57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried Gassmann, MD</last_name>
      <phone>0271 231 2260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Siegen</name>
      <address>
        <city>Siegen</city>
        <zip>D-57076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schulz, MD</last_name>
      <phone>49-271-705-0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanse-Klinikum Stralsund - Krankenhaus West</name>
      <address>
        <city>Stralsund</city>
        <zip>D-18410</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Heinz Ittel, MD</last_name>
      <phone>49-3831-35-2700</phone>
      <email>medizinische.klinik@klinikum-stralsund.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis - Straubing</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Demandt, MD</last_name>
      <phone>49-9421-90777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Aulitzky, MD</last_name>
      <phone>49-711-8101-3506</phone>
      <email>walter.aulitzky@rbk.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haematologische Praxis</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Springer, MD</last_name>
      <phone>49-711-222-0244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik fuer Onkologie - Katharinenhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Guenther Mergenthaler, MD</last_name>
      <phone>49-711-278-5601</phone>
      <email>h.mergenthaler@katharinehospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Else G. Heidemann, MD</last_name>
      <phone>49-711-991-3501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Trier</city>
        <zip>D-54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Rendenbach, MD</last_name>
      <phone>49-651-493-93</phone>
      <email>info@straurenlau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Rheumatologie und Haematologie/Internistische Onkologie</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swen H. Jacki, MD</last_name>
      <phone>49-7071-567-888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Henrik Brummendorf, MD</last_name>
      <phone>49-7071-298-0648</phone>
      <email>tim.bruemmendorf@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haematologische Praxis</name>
      <address>
        <city>Weiden</city>
        <zip>D-92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Weiss, MD</last_name>
      <phone>49-961-320-60</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Fuer Haemotologie Und Internistischer Onkologie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Fett, MD</last_name>
      <phone>49-202-449-232</phone>
      <email>fett-onkologe@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Wuppertal University Hospital</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aruna Raghavachar, MD, PhD</last_name>
      <phone>49-202-896-3351</phone>
      <email>araghavachar@wuppertal.helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamatologisch - Onkologische Praxis Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Schlag, MD</last_name>
      <phone>49-931-322-670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>D-97070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. E. Goebeler, MD</last_name>
      <phone>49-931-201-7080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <zip>CH 4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Weber-Stadelmann, MD</last_name>
      <phone>41-61-261-0225</phone>
      <email>cancer@bluewin.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011 Apr 20;29(12):1634-42. doi: 10.1200/JCO.2010.32.0598. Epub 2011 Mar 21.</citation>
    <PMID>21422420</PMID>
  </results_reference>
  <results_reference>
    <citation>Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010 Mar 10;28(8):1429-35. doi: 10.1200/JCO.2009.25.5075. Epub 2010 Feb 8.</citation>
    <PMID>20142590</PMID>
  </results_reference>
  <results_reference>
    <citation>Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German CML Study Group.. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010 Mar 11;115(10):1880-5. doi: 10.1182/blood-2009-08-237115. Epub 2009 Nov 18.</citation>
    <PMID>19965667</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>March 6, 2003</firstreceived_date>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
